Ionis Pharmaceuticals - IONS Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View IONS analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 1-year target prices for Ionis Pharmaceuticals' stock. Their IONS share price forecasts range from $27.00 to $67.00. On average, they anticipate the company's share price to reach $45.17 in the next twelve months. This suggests a possible upside of 26.4% from the stock's current price.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.

Ionis Pharmaceuticals' stock was trading at $37.77 at the beginning of the year. Since then, IONS stock has decreased by 5.4% and is now trading at $35.74.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our IONS earnings forecast.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its earnings results on Wednesday, February, 22nd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.69. The business earned $152 million during the quarter, compared to analyst estimates of $160.21 million. Ionis Pharmaceuticals had a negative net margin of 45.75% and a negative trailing twelve-month return on equity of 43.01%. Ionis Pharmaceuticals's revenue was down 65.5% on a year-over-year basis. During the same period last year, the firm earned $1.41 earnings per share.

ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Direxion mRNA ETF (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Franklin Genomic Advancements ETF (HELX), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC).

Ionis Pharmaceuticals updated its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $672.18 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IONS stock can currently be purchased for approximately $35.74.

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.11 billion and generates $587 million in revenue each year. The company earns $-269,720,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.

The company employs 660 workers across the globe.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700.